Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world

Anselm K Gitt; Dominik Lautsch; Jean Ferrières; Gaetano M De Ferrari; Ami Vyas; Carl A Baxter; Lori D Bash; Veronica Ashton; Martin Horack; Wael Almahmeed; Fu-Tien Chiang; Kian Keong Poh; Philippe Brudi; Baishali Ambegaonkar

doi:10.1016/j.dib.2018.04.092

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world

Data Brief. 2018 May 1:18:1937-1940. doi: 10.1016/j.dib.2018.04.092. eCollection 2018 Jun.

Authors

Anselm K Gitt^{1

2}, Dominik Lautsch³, Jean Ferrières⁴, Gaetano M De Ferrari⁵, Ami Vyas⁶, Carl A Baxter⁷, Lori D Bash³, Veronica Ashton⁸, Martin Horack², Wael Almahmeed^{9

10}, Fu-Tien Chiang^{11

12}, Kian Keong Poh^{13

14}, Philippe Brudi³, Baishali Ambegaonkar³

Affiliations

¹ Herzzentrum Ludwigshafen, Germany.
² Institut für Herzinfarktforschung, Ludwigshafen, Germany.
³ Merck&Co, Inc., Kenilworth, NJ, USA.
⁴ Rangueil hospital, Toulouse university school of medicine, Toulouse, France.
⁵ Department of Molecular Medicine University of Pavia, and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
⁶ Rutgers University, School of Public Health, Piscataway, NJ, USA.
⁷ Merck Sharp & Dohme, Corp., Hertford Road, Hoddesdon, UK.
⁸ Agile-1 for Merck & Co., Inc., Kenilworth, NJ, USA.
⁹ Sheikh Khalifa Medical City, Abu Dhabi, UAE.
¹⁰ Heart and Vascular Institute, Cleveland Clinic, Abu Dhabi, UAE.
¹¹ National Taiwan University Hospital, Taipei, Taiwan.
¹² Fu-Jen Catholic University Hospital, Taipei, Taiwan.
¹³ Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
¹⁴ Department of Cardiology, National University Heart Center Singapore, National University Health System, Singapore.

Abstract

DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 patients (93.8%) were on active lipid lowering therapy (LLT). The mean atorvastatin dose equivalent was 25 mg per day and 10.5% received ezetimibe in combination with a statin. The mean low-density lipoprotein cholesterol (LDL-C) level was 88 mg/dL, with 29.4% of patients displaying a level below the 70 mg/dL target for very high-risk subjects.

Conclusion: While more than 90% of patients with CHD were on lipid lowering drugs, only three out of ten patients achieved their LDL-C target value.

Keywords: Global; Low-density lipoprotein cholesterol; Region; Statins; Treatment target.